These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23387497)

  • 1. Guanylyl cyclase C as a biomarker in colorectal cancer.
    Hyslop T; Waldman SA
    Biomark Med; 2013 Feb; 7(1):159-67. PubMed ID: 23387497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients.
    Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
    Expert Rev Mol Diagn; 2009 Nov; 9(8):777-85. PubMed ID: 19895223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer.
    Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
    Clin Cancer Res; 2011 May; 17(10):3293-303. PubMed ID: 21307149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular staging estimates occult tumor burden in colorectal cancer.
    Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
    Adv Clin Chem; 2010; 52():19-39. PubMed ID: 21275338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
    Waldman SA; Hyslop T; Schulz S; Barkun A; Nielsen K; Haaf J; Bonaccorso C; Li Y; Weinberg DS
    JAMA; 2009 Feb; 301(7):745-52. PubMed ID: 19224751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does stage II colorectal cancer need to be redefined?
    Grothey A
    Clin Cancer Res; 2011 May; 17(10):3053-5. PubMed ID: 21498396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GUCY2C molecular staging personalizes colorectal cancer patient management.
    Gong JP; Schulz S; Hyslop T; Waldman SA
    Biomark Med; 2012 Jun; 6(3):339-48. PubMed ID: 22731908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Previstage GCC test for staging patients with colorectal cancer.
    Mejia A; Waldmana SA
    Expert Rev Mol Diagn; 2008 Sep; 8(5):571-8. PubMed ID: 18785805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular staging of node negative patients with colorectal cancer.
    Hyslop T; Waldman SA
    J Cancer; 2013; 4(3):193-9. PubMed ID: 23459453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.
    Cagir B; Gelmann A; Park J; Fava T; Tankelevitch A; Bittner EW; Weaver EJ; Palazzo JP; Weinberg D; Fry RD; Waldman SA
    Ann Intern Med; 1999 Dec; 131(11):805-12. PubMed ID: 10610624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer.
    Carlson MR
    Mol Diagn Ther; 2009; 13(1):11-4. PubMed ID: 19351210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
    Waldman SA; Cagir B; Rakinic J; Fry RD; Goldstein SD; Isenberg G; Barber M; Biswas S; Minimo C; Palazzo J; Park PK; Weinberg D
    Dis Colon Rectum; 1998 Mar; 41(3):310-5. PubMed ID: 9514425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular staging individualizing cancer management.
    Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
    J Surg Oncol; 2012 Apr; 105(5):468-74. PubMed ID: 22441898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokeratin 20 and guanylyl cyclase C mRNA is largely present in lymph node and liver specimens of colorectal cancer patients.
    Conzelmann M; Dieterle CP; Linnemann U; Berger MR
    Int J Cancer; 2003 Nov; 107(4):617-28. PubMed ID: 14520701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer.
    Frick GS; Pitari GM; Weinberg DS; Hyslop T; Schulz S; Waldman SA
    Expert Rev Mol Diagn; 2005 Sep; 5(5):701-13. PubMed ID: 16149873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer.
    Schulz S; Hyslop T; Haaf J; Bonaccorso C; Nielsen K; Witek ME; Birbe R; Palazzo J; Weinberg D; Waldman SA
    Clin Cancer Res; 2006 Aug; 12(15):4545-52. PubMed ID: 16899600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.
    Li P; Waldman SA
    Cancer Biol Ther; 2010 Aug; 10(3):211-8. PubMed ID: 20592492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
    Winn B; Tavares R; Matoso A; Noble L; Fanion J; Waldman SA; Resnick MB
    Hum Pathol; 2010 Jan; 41(1):123-8. PubMed ID: 19800103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis.
    Sargent DJ; Resnick MB; Meyers MO; Goldar-Najafi A; Clancy T; Gill S; Siemons GO; Shi Q; Bot BM; Wu TT; Beaudry G; Haince JF; Fradet Y
    Ann Surg Oncol; 2011 Nov; 18(12):3261-70. PubMed ID: 21533822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.
    Hyslop T; Weinberg DS; Schulz S; Barkun A; Waldman SA
    Cancer; 2012 May; 118(9):2532-40. PubMed ID: 21887684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.